Literature DB >> 2295216

Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1.

O Mortimer1, K Persson, M G Ladona, D Spalding, U M Zanger, U A Meyer, A Rane.   

Abstract

We studied the oxidation capacity in liver biopsies of a series of extensive metabolizers (n = 10) and poor metabolizers (n = 2) as identified by in vivo phenotyping with dextromethorphan. Codeine and dextromethorphan were used as probe drugs in vitro. The data were compared with the contents of cytochrome P-450IID1 as quantitated by Western immunoblotting by use of a specific monoclonal antibody (MAb 114/2). The O-demethylation of codeine was highly correlated with the O-demethylation of dextromethorphan (r = 0.90). The N-demethylation of codeine was catalyzed at a considerably higher rate than the O-demethylation. The N-demethylation to O-demethylation ratio of codeine was 46 in the poor metabolizer and, on average, 6.2 (range, 2.6 to 11) in the extensive metabolizers, respectively. The band intensity in Western blots correlated with the rate of O-demethylation of codeine (r = 0.95) and of dextromethorphan (r = 0.88) in the extensive metabolizers. The comeasurement of the O-demethylation and N-demethylation of codeine may provide a tool with which to phenotype individuals in vitro with respect to the polymorphism of the cytochrome P-450IID1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295216     DOI: 10.1038/clpt.1990.4

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  Pharmacological and toxicological significance of brain cytochromes P450.

Authors:  V Ravindranath
Journal:  Neurotox Res       Date:  2001-08       Impact factor: 3.911

Review 2.  Pharmacogenomics: a systems approach.

Authors:  Liewei Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010 Jan-Feb

3.  The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.

Authors:  Xiujun Wu; Li Yuan; Jinliang Zuo; Jing Lv; Tao Guo
Journal:  Eur J Clin Pharmacol       Date:  2014-01       Impact factor: 2.953

4.  Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism.

Authors:  Z Liu; O Mortimer; C A Smith; C R Wolf; A Rane
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

5.  Infants and young children metabolise codeine to morphine. A study after single and repeated rectal administration.

Authors:  H Quiding; G L Olsson; L O Boreus; U Bondesson
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

6.  Impact of environmental and genetic factors on codeine analgesia.

Authors:  J Desmeules; M P Gascon; P Dayer; M Magistris
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.

Authors:  Stacy S Shord; Larisa H Cavallari; Weihua Gao; Hyun-Young Jeong; Kelly Deyo; Shitalben R Patel; Joseph R Camp; Susan M Labott; Robert E Molokie
Journal:  Eur J Clin Pharmacol       Date:  2009-04-09       Impact factor: 2.953

8.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.

Authors:  D Wu; S V Otton; B A Sproule; U Busto; T Inaba; W Kalow; E M Sellers
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  In vitro forecasting of drugs that may interfere with codeine bioactivation.

Authors:  P Dayer; J Desmeules; R Striberni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.